Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data

Takahisa Kawamura, Hidefumi Kasai, Valentina Fermanelli, Toshiaki Takahashi, Yukinori Sakata, Toshiyuki Matsuoka, Mika Ishii, Yusuke Tanigawara

Research output: Contribution to journalArticle

Abstract

Postmarketing surveillance is useful to collect safety data in real-world clinical settings. In this study, we applied postmarketing real-world data on a mechanistic model analysis for neutropenic profiles of eribulin in patients with recurrent or metastatic breast cancer. Demographic and safety data were collected using an active surveillance method from eribulin-treated recurrent or metastatic breast cancer patients. Changes in neutrophil counts over time were analyzed using a mechanistic pharmacodynamic model. Pathophysiological factors that might affect the severity of neutropenia were investigated, and neutropenic patterns were simulated for different treatment schedules. Clinical and laboratory data were collected from 401 patients (5199 neutrophil count measurements) who had not received granulocyte colony-stimulating factor and were eligible for pharmacodynamic analysis. The estimated mean parameters were as follows: mean transit time = 104.5 h, neutrophil proliferation rate constant = 0.0377 h-1, neutrophil elimination rate constant = 0.0295 h-1, and linear coefficient of drug effect = 0.0413 mL/ng. Low serum albumin levels and low baseline neutrophil counts were associated with severe neutropenia. The probability of grade ≥3 neutropenia was predicted to be 69%, 27%, and 27% for patients on standard, biweekly, and triweekly treatment scenarios, respectively, based on virtual simulations using the developed pharmacodynamic model. In conclusion, this is the first application of postmarketing surveillance data to a model-based safety analysis. This analysis of safety data reflecting authentic clinical settings will provide useful information on the safe use and potential risk factors of eribulin.

Original languageEnglish
JournalCancer Science
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

eribulin
Neutrophils
Breast Neoplasms
Safety
Neutropenia
Granulocyte Colony-Stimulating Factor
Serum Albumin
Appointments and Schedules
Demography

Keywords

  • Eribulin
  • Neutropenia
  • Pharmacodynamic
  • Pharmacometric
  • Postmarketing surveillance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data. / Kawamura, Takahisa; Kasai, Hidefumi; Fermanelli, Valentina; Takahashi, Toshiaki; Sakata, Yukinori; Matsuoka, Toshiyuki; Ishii, Mika; Tanigawara, Yusuke.

In: Cancer Science, 01.01.2018.

Research output: Contribution to journalArticle

Kawamura, Takahisa ; Kasai, Hidefumi ; Fermanelli, Valentina ; Takahashi, Toshiaki ; Sakata, Yukinori ; Matsuoka, Toshiyuki ; Ishii, Mika ; Tanigawara, Yusuke. / Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data. In: Cancer Science. 2018.
@article{7c59ef21b97c4fbfa87ef810f0df754e,
title = "Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data",
abstract = "Postmarketing surveillance is useful to collect safety data in real-world clinical settings. In this study, we applied postmarketing real-world data on a mechanistic model analysis for neutropenic profiles of eribulin in patients with recurrent or metastatic breast cancer. Demographic and safety data were collected using an active surveillance method from eribulin-treated recurrent or metastatic breast cancer patients. Changes in neutrophil counts over time were analyzed using a mechanistic pharmacodynamic model. Pathophysiological factors that might affect the severity of neutropenia were investigated, and neutropenic patterns were simulated for different treatment schedules. Clinical and laboratory data were collected from 401 patients (5199 neutrophil count measurements) who had not received granulocyte colony-stimulating factor and were eligible for pharmacodynamic analysis. The estimated mean parameters were as follows: mean transit time = 104.5 h, neutrophil proliferation rate constant = 0.0377 h-1, neutrophil elimination rate constant = 0.0295 h-1, and linear coefficient of drug effect = 0.0413 mL/ng. Low serum albumin levels and low baseline neutrophil counts were associated with severe neutropenia. The probability of grade ≥3 neutropenia was predicted to be 69{\%}, 27{\%}, and 27{\%} for patients on standard, biweekly, and triweekly treatment scenarios, respectively, based on virtual simulations using the developed pharmacodynamic model. In conclusion, this is the first application of postmarketing surveillance data to a model-based safety analysis. This analysis of safety data reflecting authentic clinical settings will provide useful information on the safe use and potential risk factors of eribulin.",
keywords = "Eribulin, Neutropenia, Pharmacodynamic, Pharmacometric, Postmarketing surveillance",
author = "Takahisa Kawamura and Hidefumi Kasai and Valentina Fermanelli and Toshiaki Takahashi and Yukinori Sakata and Toshiyuki Matsuoka and Mika Ishii and Yusuke Tanigawara",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/cas.13708",
language = "English",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data

AU - Kawamura, Takahisa

AU - Kasai, Hidefumi

AU - Fermanelli, Valentina

AU - Takahashi, Toshiaki

AU - Sakata, Yukinori

AU - Matsuoka, Toshiyuki

AU - Ishii, Mika

AU - Tanigawara, Yusuke

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Postmarketing surveillance is useful to collect safety data in real-world clinical settings. In this study, we applied postmarketing real-world data on a mechanistic model analysis for neutropenic profiles of eribulin in patients with recurrent or metastatic breast cancer. Demographic and safety data were collected using an active surveillance method from eribulin-treated recurrent or metastatic breast cancer patients. Changes in neutrophil counts over time were analyzed using a mechanistic pharmacodynamic model. Pathophysiological factors that might affect the severity of neutropenia were investigated, and neutropenic patterns were simulated for different treatment schedules. Clinical and laboratory data were collected from 401 patients (5199 neutrophil count measurements) who had not received granulocyte colony-stimulating factor and were eligible for pharmacodynamic analysis. The estimated mean parameters were as follows: mean transit time = 104.5 h, neutrophil proliferation rate constant = 0.0377 h-1, neutrophil elimination rate constant = 0.0295 h-1, and linear coefficient of drug effect = 0.0413 mL/ng. Low serum albumin levels and low baseline neutrophil counts were associated with severe neutropenia. The probability of grade ≥3 neutropenia was predicted to be 69%, 27%, and 27% for patients on standard, biweekly, and triweekly treatment scenarios, respectively, based on virtual simulations using the developed pharmacodynamic model. In conclusion, this is the first application of postmarketing surveillance data to a model-based safety analysis. This analysis of safety data reflecting authentic clinical settings will provide useful information on the safe use and potential risk factors of eribulin.

AB - Postmarketing surveillance is useful to collect safety data in real-world clinical settings. In this study, we applied postmarketing real-world data on a mechanistic model analysis for neutropenic profiles of eribulin in patients with recurrent or metastatic breast cancer. Demographic and safety data were collected using an active surveillance method from eribulin-treated recurrent or metastatic breast cancer patients. Changes in neutrophil counts over time were analyzed using a mechanistic pharmacodynamic model. Pathophysiological factors that might affect the severity of neutropenia were investigated, and neutropenic patterns were simulated for different treatment schedules. Clinical and laboratory data were collected from 401 patients (5199 neutrophil count measurements) who had not received granulocyte colony-stimulating factor and were eligible for pharmacodynamic analysis. The estimated mean parameters were as follows: mean transit time = 104.5 h, neutrophil proliferation rate constant = 0.0377 h-1, neutrophil elimination rate constant = 0.0295 h-1, and linear coefficient of drug effect = 0.0413 mL/ng. Low serum albumin levels and low baseline neutrophil counts were associated with severe neutropenia. The probability of grade ≥3 neutropenia was predicted to be 69%, 27%, and 27% for patients on standard, biweekly, and triweekly treatment scenarios, respectively, based on virtual simulations using the developed pharmacodynamic model. In conclusion, this is the first application of postmarketing surveillance data to a model-based safety analysis. This analysis of safety data reflecting authentic clinical settings will provide useful information on the safe use and potential risk factors of eribulin.

KW - Eribulin

KW - Neutropenia

KW - Pharmacodynamic

KW - Pharmacometric

KW - Postmarketing surveillance

UR - http://www.scopus.com/inward/record.url?scp=85050495688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050495688&partnerID=8YFLogxK

U2 - 10.1111/cas.13708

DO - 10.1111/cas.13708

M3 - Article

C2 - 29933506

AN - SCOPUS:85050495688

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -